GZMB and cancer: Quantitative flow cytometric analysis also confirmed that the fluorescence signal of the probe H5 in cancer cells preceded that of Sytox Blue, which corroborates active GzmB as an early biomarker of immune-mediated cancer cell death (Fig. 2f).